FIELD: medicine.
SUBSTANCE: present invention refers to new pharmaceutical oral compositions on the basis of products containing lipases, first of all pancreatine and pancreatine-containing products, or enzyme-containing products containing at least one lipase of non-animal, first of all microbiological origin. Said pharmaceutical compositions are characterised with improved lipolytic activity, first of all lipase stabilisation in acid interval pH. Such new pharmaceutical compositions contain a system containing at least one surfactant and one co-surfactant and optionally a lipophilic phase which spontaneously form emulsions when contacting with hydrophilic and lipophilic phases.
EFFECT: new pharmaceutical compositions are intended for treatment and-or prevention of indigestions, first of all those caused by chronic exocrinous insufficiency of pancreas in mammals and human.
30 cl, 5 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF PRODUCING COMPOSITIONS WITH IMPROVED SAFETY PROFILE CONTAINING PANCREATIN, AND COMPOSITIONS SUITABLE FOR PHARMACEUTICAL USE | 2015 |
|
RU2712142C2 |
| MICROEMULSION COMPOSITIONS INCLUDING SUBSTANCE P ANTAGONISTS | 2005 |
|
RU2397759C2 |
| PRELIMINARY PREPARED EMULSION CONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDE | 1999 |
|
RU2235554C2 |
| COMPOSITION FOR REGULATION OF LIPASE-CATALISED REACTIONS | 2008 |
|
RU2491057C2 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING CAMPTOTHECIN DERIVATIVE | 2012 |
|
RU2620331C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES OF N-SULFONYLINDOLINE | 1997 |
|
RU2174394C2 |
| PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC THERAPEUTIC AGENTS AND COMPOSITIONS CONTAINING IT | 2006 |
|
RU2429850C2 |
| PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC MEDICINAL PRODUCTS AND COMPOSITIONS CONTAINING THEM | 2006 |
|
RU2623206C2 |
| PROTEASES FOR PHARMACEUTICAL APPLICATION | 2006 |
|
RU2420578C2 |
| PANCREATINE DIALYSIS PROCEDURE AND PANCREATINE COMPOUNDS | 2004 |
|
RU2359270C2 |
